Abstract Number: 2635 • ACR Convergence 2025
Differences in structural lesions of the spine between patients with early axSpA and non-axSpA chronic back pain: 2-year results of the SPACE Cohort
Background/Purpose: The difference in spinal structural lesions and their progression over time between chronic back pain (CBP) patients with and without early axSpA is unknown.…Abstract Number: 2334 • ACR Convergence 2025
Development and validation analysis of a Corrected Axial Spondyloarthritis Metrology Index
Background/Purpose: The MOBILITY study, a study on spinal mobility measures in healthy individuals, showed that the Bath Ankylosing Spondylitis Metrology Index (BASMI) often overestimates spinal…Abstract Number: 2131 • ACR Convergence 2025
Transition from Juvenile Dermatomyositis to Spondyloarthritis: A Novel Overlapping Inflammatory Phenotype
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare inflammatory disease primarily affecting muscle, skin, and vasculature. Characterized by muscle weakness, distinctive skin lesions, and autoantibodies, it…Abstract Number: 1452 • ACR Convergence 2025
Clinical and Demographic Characteristics of Treatment-Refractory Axial Spondyloarthritis: Data from the Greek AxSpA Registry
Background/Purpose: Axial spondyloarthritis (AxSpA) is a chronic inflammatory disease that significantly impairs quality of life. Although biologic and targeted synthetic DMARDs (b/tsDMARDs) have improved disease…Abstract Number: 1407 • ACR Convergence 2025
Trends in Diagnostic Timing and Clinical Features of Axial Spondyloarthritis by Sex and Clinical Subtype: A Multicenter Cohort Over Seven Decades
Background/Purpose: Axial Spondyloarthritis (axSpA) frequently eludes early recognition, particularly before structural sacroiliitis becomes visible. We analyzed decade-specific diagnosis delay, clinical subtype distribution, and first-symptom profiles…Abstract Number: 0554 • ACR Convergence 2025
Real world experience with generic Tofacitinib in Axial Spondyloarthritis from North India
Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory condition that falls under the category of spondyloarthritis (SpA) and significantly affects quality of life, causing symptoms like…Abstract Number: 0534 • ACR Convergence 2025
Prevalence and Impact of Fibromyalgia on Disease Outcomes and Treatment in Axial Spondyloarthritis: 10-year Follow-up Data From the DESIR Cohort
Background/Purpose: Concomitant fibromyalgia (FM) can be suspected in patients (pts) with axial SpA (axSpA) using the Fibromyalgia Rapid Screening Tool (FiRST).The objective of this study…Abstract Number: 0103 • ACR Convergence 2025
Common and Rare Variant Contributions to Familial Aggregation in Spondyloarthritis
Background/Purpose: Spondyloarthritis (SpA) exhibits strong familial aggregation, with close relatives of patients having a significantly higher risk of developing the disease. This pattern might be…Abstract Number: 2634 • ACR Convergence 2025
Sex differences in medication discontinuation in axial spondyloarthritis
Background/Purpose: Women with axial spondyloarthritis (axSpA) tend to report worse outcomes and greater functional impairment than men. They may also respond less favorably to medication,…Abstract Number: 2333 • ACR Convergence 2025
Validation of a Corrected Axial Spondyoarthritis Metrology Index in 9 Randomized Clinical Trials
Background/Purpose: The MOBILITY study showed that BASMI often misclassifies spinal mobility, especially in older and taller individuals. To address this, the Corrected AxSpA Metrology Index…Abstract Number: 2038 • ACR Convergence 2025
Real-World Use of Dual Targeted Therapy in Rheumatic Disease: A Single-Center Case Series
Background/Purpose: Combination therapy with two biologic agents (bDMARDs) or a biologic plus a Janus kinase inhibitor (JAKi) is rarely used in rheumatology due to safety…Abstract Number: 1451 • ACR Convergence 2025
Bimekizumab was Efficacious Regardless of Age, BMI, CRP, or HLA-B27 Status: 1-Year Results from Two Phase 3 Studies
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL-17A, has shown efficacy to Week (Wk) 52 in patients…Abstract Number: 1408 • ACR Convergence 2025
When Damage and Disability Diverge: Unraveling Sex-Based Drivers of Axial Spondyloarthritis Burden
Background/Purpose: Sex differences in axial spondyloarthritis (axSpA) are well recognized, but their clinical consequences remain understudied in real-world settings. This study aimed to assess sex-based…Abstract Number: 0552 • ACR Convergence 2025
Radiographic Sacroiliitis Progression in Psoriatic Arthritis
Background/Purpose: Radiographic sacroiliitis is an important indicator of axial involvement psoriatic arthritis (PsA), but only little is known about factors associated with progression of sacroiliitis.…Abstract Number: 0530 • ACR Convergence 2025
Evaluating ChatGPT’s Performance in Diagnosing Low Back Pain: A Comparison with Clinicians and Impact of Prompted Specialties
Background/Purpose: Low back pain (LBP) is a multifactorial condition managed by various specialists. AI chatbots like ChatGPT may help clinicians identify probable diagnoses. Given that…
- « Previous Page
 - 1
 - …
 - 6
 - 7
 - 8
 - 9
 - 10
 - …
 - 49
 - Next Page »
 
